Ramadevi Medavarapu, MD
Hematology & Oncology · Las Cruces, NMNPI 1427298520
Payments from drug & device makers
Across 116 payments — averaging $26.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$794
- E.r. Squibb & Sons, L.L.C.$287
- Johnson & Johnson$232
- Gilead$201
- Novartis$155
- Daiichi Sankyo Inc.$112
- plus $1K from 30 others
What the payments were for
- Food & beverage$2,17092%
- Education$1968%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 14 | $794 |
| E.r. Squibb & Sons, L.L.C. | 10 | $287 |
| Johnson & Johnson | 10 | $232 |
| Gilead | 9 | $201 |
| Novartis | 7 | $155 |
| Daiichi Sankyo Inc. | 6 | $112 |
| AstraZeneca(2 entities) | 4 | $92 |
| Bayer | 5 | $90 |
| Caris MPI, Inc. | 4 | $87 |
| Progenics Pharmaceuticals, Inc. | 2 | $83 |
| Amgen | 4 | $78 |
| Pfizer | 4 | $78 |
| Pharmacosmos Therapeutics Inc. | 3 | $67 |
| EMD Serono, Inc. | 3 | $65 |
| Seagen Inc. | 3 | $62 |
| Eisai Inc. | 3 | $59 |
| Exelixis Inc. | 3 | $51 |
| Amneal Pharmaceuticals LLC | 2 | $50 |
| Deciphera Pharmaceuticals Inc. | 1 | $37 |
| Astellas Pharma US Inc | 2 | $36 |
| Incyte Corporation | 2 | $36 |
| AbbVie | 1 | $33 |
| Sanofi | 1 | $28 |
| GSK | 1 | $28 |
| Tempus AI, Inc | 1 | $27 |
| Regeneron Healthcare Solutions, Inc. | 1 | $25 |
| Rigel Pharmaceuticals, Inc. | 1 | $25 |
| Agios Pharmaceuticals, Inc. | 1 | $24 |
| Taiho Oncology, Inc. | 1 | $22 |
| Sobi, Inc | 1 | $22 |
| Geron Corporation | 1 | $16 |
| Portola Pharmaceuticals, LLC | 1 | $16 |
| Genmab U.S., Inc. | 1 | $16 |
| Adaptive Biotechnologies Corporation | 1 | $14 |
| Lilly USA, LLC | 1 | $14 |
| Beone Medicines USA, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EMPLICITI$122
How this compares
$3,077 in reported general payments places this provider in the 35th percentile of 54 hematology & oncology providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 46 | $928,394 |
| CabometyxCabozantinib S-Malate | 36 | $827,120 |
| ScemblixAsciminib Hydrochloride | 25 | $527,747 |
| PromactaEltrombopag Olamine | 14 | $486,510 |
| VenclextaVenetoclax | 40 | $467,684 |
| LenvimaLenvatinib Mesylate | 20 | $454,517 |
| VerzenioAbemaciclib | 32 | $436,667 |
| AyvakitAvapritinib | 11 | $419,733 |
| TagrissoOsimertinib Mesylate | 24 | $390,130 |
| PomalystPomalidomide | 13 | $292,240 |
| Lenalidomide | 21 | $267,866 |
| LynparzaOlaparib | 12 | $232,776 |
| ErleadaApalutamide | 14 | $201,194 |
| AlecensaAlectinib Hcl | 13 | $178,856 |
| XalkoriCrizotinib | 12 | $135,246 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisScemblix, Promacta | $155 | $1,014,25639 claims |
| Exelixis Inc.Cabometyx | $51 | $827,12036 claims |
| AstraZenecaTagrisso, Lynparza | $92 | $622,90536 claims |
| AbbVieVenclexta | $33 | $467,68440 claims |
| Eisai Inc.Lenvima | $59 | $454,51720 claims |
| Lilly USA, LLCVerzenio | $14 | $436,66732 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $287 | $292,24013 claims |
| PfizerXalkori, Eliquis | $78 | $264,743207 claims |
| Johnson & JohnsonErleada, Xarelto | $232 | $238,08444 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $50 | $735125 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 54 hematology & oncology providers in New Mexico.
Other hematology & oncology in Las Cruces
- Ikenna OsuorjiLas Cruces$1K
- Ursa Brown GlabermanAlbuquerque$5M
- Neda Hashemi SadraeiAlbuquerque$1.6M
- Olivier RixeAlbuquerque$1.6M
- Jeffrey NeidhartFarmington$1.5M
- Emrullah YilmazAlbuquerque$1.3M
- Erika MaestasAlbuquerque$880K
- Sardar ImamFarmington$647K
- Jose AvitiaAlbuquerque$553K
- Jacklyn NemunaitisAlbuquerque$351K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.